Completed PHASE1 INTERVENTIONAL 3-arm NCT03976687

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EYP001a in Healthy Volunteers and Nonalcoholic Steatohepatitis Patients

A Phase 1b, Open-label Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FXR Agonist/Modulator EYP001a in Healthy Volunteers and Nonalcoholic Steatohepatitis Patients

Sponsor: Enyo Pharma

Conditions Healthy NASH - Nonalcoholic Steatohepatitis

Interventions EYP001a

Updated 8 times since 2019 Last updated: Sep 24, 2020 Started: Jun 11, 2019 Primary completion: May 25, 2020 Completion: May 25, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Healthy and NASH - Nonalcoholic Steatohepatitis, this trial is completed. The trial is conducted by Enyo Pharma and has accumulated 8 data snapshots since 2019. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Oct 2020 — Jan 2021 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Aug 2020 — Oct 2020 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting

▶ Show 3 earlier versions

Oct 2019 — Aug 2020 [monthly]

Recruiting PHASE1
Aug 2019 — Oct 2019 [monthly]

Recruiting PHASE1
Jul 2019 — Aug 2019 [monthly]

Recruiting PHASE1

First recorded

Jun 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Enyo Pharma

Data source: Enyo Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Randwick, Australia